UniQure's Fabry Disease Treatment Gets Orphan Drug Designation from FDA
By Denny Jacob
Gene therapy company uniQure disclosed that the Food and Drug Administration granted orphan drug designation to AMT-191, a potential treatment for Fabry disease.
Fabry disease is a genetic disorder resulting from a deficiency of the galactosidase alpha gene which can then affect multiple systems in the body.
The FDA's orphan drug designation provides certain incentives including tax credits and certain administrative fees for clinical trials being waived. It provides a special status for investigational drugs being developed for rare diseases considered to affect only up to 200,000 people in the U.S.
UniQure disclosed the dosing of the first patient in its Phase 1/2a trial of AMT-191 in August, which is being conducted in the U.S.
Chief Medical Officer Walid Abi-Saab said the company is looking forward to generating proof-of-concept data and providing initial data in 2025.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
September 23, 2024 07:51 ET (11:51 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst